Salvation for women. Scientists are testing a vaccine against breast cancer
Researchers at the Cleveland Clinic have begun the next step in vaccine research aimed at preventing the most aggressive and lethal form of breast cancer.
The new study will involve healthy people at high risk for developing breast cancer (BC) who choose to voluntarily undergo prophylactic breast removal to reduce their risk, writes Labiotech .
At Focus. Technologies has its own Telegram channel . Subscribe to not miss the latest and exciting news from the world of science!
People in this category usually carry genetic mutations that put them at risk of developing triple negative breast cancer or have a high family risk of any breast cancer. The study, conducted on the main campus of the Cleveland Clinic in Ohio, evaluates the safety and ability to control the immune response.
It enrolls approximately 6-12 patients and is expected to be completed by the end of 2023. Study participants will receive three shots two weeks apart and will be closely monitored for side effects and immune response.
The Phase 1B clinical trial follows the ongoing Phase 1A trial, which began in 2021 and is expected to be completed in the fourth quarter of 2023. The Phase 1A study includes patients who have completed treatment for triple-negative early-stage breast cancer within the past three years and are currently tumor-free but at high risk of recurrence.
“Triple-negative breast cancer is the form of the disease for which we have the least effective treatments,” said J. Thomas Budd of the Cleveland Clinic’s Taussig Cancer Institute and principal investigator. In the long term, we hope this could become a true preventive vaccine. that could be administered to people without cancer to prevent them from developing this highly aggressive disease.”
Budd said there is a great need for improved treatments for triple-negative breast cancer, which lacks the biological characteristics that would normally respond to hormone or targeted therapy. Although it accounts for only 12% to 15% of all breast cancers, triple negative breast cancer accounts for a disproportionately higher percentage of deaths. It is twice as common in black women, and about 70 to 80% of breast tumors that occur in women with mutations in the BRCA1 gene.
